Patent application number | Description | Published |
20090142800 | Secreted and transmembrane polypeptides and nucleic acids encoding the same - The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 06-04-2009 |
20090170158 | Secreted and transmembrane polypeptides and nucleic acids encoding the same - The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 07-02-2009 |
20090191184 | DcR3 polypeptide, A TNFR homolog - A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided. | 07-30-2009 |
20090197301 | Secreted and transmembrane polypeptides and nucleic acids encoding the same - The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 08-06-2009 |
20100080793 | DcR3 polypeptide, A TNFR homolog - A TNFR homolog, identified as DcR | 04-01-2010 |
20100221249 | WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME - Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides. | 09-02-2010 |
20110311540 | WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME - Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides. | 12-22-2011 |
Patent application number | Description | Published |
20090098603 | POLYPEPTIDES SHARING SEQUENCE IDENTITY WITH A FIBROBLAST GROWTH FACTOR POLYPEPTIDE AND NUCLEIC ACIDS ENCODING THE SAME - The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation. | 04-16-2009 |
20090264307 | ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE RESOLUTION - Disclosed herein is a system useful for detecting sequence differences (e.g., single-nucleotide polymorphisms) between genomes using data from a single hybridization with a genomic DNA microarray, such as a whole-genome array. The methods described herein can be used to detect, simply and inexpensively, differences in sequence among the genomes of individual members of a species, for example. In examples described herein, the system and methods were used to detect a variety of spontaneous single base-pair substitutions, insertions and deletions, and most (>90%) of the approximately 30,000 known single-nucleotide polymorphisms between two | 10-22-2009 |
20100143926 | Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression - Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival. | 06-10-2010 |
20110207912 | FGF-19 NUCLEIC ACIDS - The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation. | 08-25-2011 |
20140128287 | SYSTEMS FOR INDUCTION OF GENE EXPRESSION AND PROTEIN DEPLETION IN YEAST - A system allows for rapid and specific induction of individual genes in eukaryotic cells using a chimeric transcriptional activator that is responsive to hormone inducer. Upon addition of the hormone, cytoplasmic transcriptional activator localizes to the nucleus and subsequently binds to promoters containing sequences that bind to its DNA-binding domain. Genetic modifications allow for rapid and specific degradation of a targeted protein upon addition of hormone by means of a regulated degron method that utilizes a protease variant. This system is useful for discovering new compounds by high throughput screening when introducing compound libraries to these protein-depleted cells. | 05-08-2014 |